Antimicrobial Susceptibility Testing Market Size, Share, Growth Analysis, By Test type(Phenotypic testing, genotypic testing, and rapid testing), By End user(Hospitals and diagnostic laboratories, research and academic institutes, and pharmaceutical and biotechnology companies), By Product type(Instruments, reagents and kits, and software and services), By Region - Industry Forecast 2024-2031

Global Antimicrobial Susceptibility Testing Market size was valued at USD 3.79 billion in 2022 and is poised to grow from USD 3.98 billion in 2023 to USD 5.69 billion by 2031, at a CAGR of 5.2% during the forecast period (2024-2031).

The competitive landscape of the global antimicrobial susceptibility testing market presents a combination of a plethora of market players, engaged in offering effective technologies and products. The leading market players like Becton, Dickinson and Company (BD), Thermo Fisher Scientific, Siemens Healthineers, and bioMérieux are focused on offering integrated solutions, innovative diagnostic technologies, and improved microbiology systems. Companies are also investing in R&D to develop improved testing methods and strategic alliances to expand market reach. Overall, the market is differentiated by collaborations, innovations, and focus on addressing the obstacles. 'Thermo Fisher Scientific Inc. (US)', 'Bio-Rad Laboratories, Inc. (US)', 'Danaher Corporation (US)', 'Becton, Dickinson and Company (US)', 'bioMérieux SA (France)', 'Roche Diagnostics (Switzerland)', 'Abbott Laboratories (US)', 'Bruker Corporation (US)', 'Merck KGaA (Germany)', 'Agilent Technologies, Inc. (US)', 'ConvaTec Group plc (UK)', 'Cepheid (US)', 'HiMedia Laboratories Pvt. Ltd. (India)', 'Liofilchem s.r.l. (Italy)', 'Accelerate Diagnostics, Inc. (US)', 'Creative Diagnostics (US)', 'Bio-Rad Laboratories (US)', 'Synbiosis (UK)', 'ELITechGroup (France)', 'QIAGEN N.V. (Germany)'

The growth of AMR is a major threat to global health. Health organizations and authorities are focusing on the need for efficient AST to observe resistance patterns. This helps in the guidance of treatment decisions and encouraging the use of antibiotics. Also, growing cases of infectious diseases are supported by factors like travel, urbanization, and population growth that demand treatment and diagnosis. This drives the demand for effective and reliable AST. 

Growing Adoption of Rapid Testing Techniques: There is a rising focus on rapid antimicrobial susceptibility testing that offers immediate results, mostly within a few hours instead of days. Methods like mass spectrometry, molecular diagnostics, and automated systems are currently being developed to accelerate the detection of pathogens and susceptibility profiles. This is especially useful in critical care settings, wherein prompt decisions are important, affecting patient outcomes. 

Geographically, North America dominated the market in the previous years and is expected to lead over the forecast period owing to the developed healthcare infrastructure, strong research and development, and rising cases of infectious diseases. The region holds high-tech healthcare systems with superior diagnostic facilities and laboratories, allowing widespread adoption of antimicrobial susceptibility testing. There is a robust investment in research and development from private and public firms that nurture advancements and innovations in AST methods and technologies. The region also faces a large population with infectious diseases, thus impacting regional growth. The key players profiled in the region include Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, Abbott Laboratories, Agilent Technologies, Inc., and more.